Clinical Trial Search

Primary: Percentage of Participants With Veno-occlusive Disease (VOD) — 9.1; 14.3; 12.5; 5.3 Percentage of Participants

Primary: Evaluation of Safety and Tolerability Data Collected, Based on Number of Participants With Adverse Events in the LTS Phase — 365 Participants

Primary: Abaloparatide Maximum Plasma Concentration (Cmax) on Day 29 — 399.6 picograms/milliliter (pg/mL)

Primary: Time Participating in Home-Based Exercises — 46.4; 37.7 minutes

Primary: Safety (Number of Participants With Grade 3 and Higher-grade Treatment-related Adverse Events) — 13 Participants

Primary: Aspiration Risk Grade — 30; 30; 20; 9 Participants

Primary: Percentage of Participants Experiencing at Least One Treatment-Emergent Adverse Event — 78.1; 69.8 percentage of participants

Primary: Bruininks-Oseretsky Test of Motor Proficiency-Second Edition (BOT-2) — 36.4; 36.9; 36.5; 40.9 score on a scale BOT-2

Primary: Mean Brief Pain Inventory-Short Form (BPI-SF) Combined Pain Severity and Interference Score — 2.67; 2.99; 2.94; 1.90 score on a scale — p=0.13

Primary: Change From Baseline in Total Daily Physical Activity (Counts Per Minute) to Week 10-12 — -155.6 Counts per minute

Primary: Tinnitus Functional Index Change — 53.31; 44.10; 64.93 units on a scale

Primary: Fidelity of Detecting Smoking Episodes — 90.2; 9.8 percentage of events

Primary: Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48 — 88.9; 88.3 Percentage of participants

Primary: Knee Range of Motion After Manipulation Under Anesthesia — 98.7; 101.2 Degrees — p=0.23

Primary: Percentage of Warts Resolved — 80.7; 73.1 percentage of warts resolved